-
1.
Kemper MJ, Gellermann J, Habbig S, Krmar R, Dittrich K, Jungraithmayr T, et al.. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2011, Nov 9 [epub ahead of print].
-
2.
Takei T, Nitta K. Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin Exp Nephrol 2011;15:641–7.
-
3.
Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070–7.
-
4.
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al.. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011; 3:1–10.
Molecular Mechanisms of Rituximab in the Treatment of Nephrotic Syndrome
Search for other papers by Gentzon Hall in
Current site
Google Scholar
PubMed
Search for other papers by Michelle P. Winn in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory